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ABSTRACT
Our purpose was to develop recommendations for contouring the computed tomography (CT)-based high-risk
clinical target volume (CTVHR) for 3D image-guided brachytherapy (3D-IGBT) for cervical cancer. A 15-member
Japanese Radiation Oncology Study Group (JROSG) committee with expertise in gynecological radiation oncology
initiated guideline development for CT-based CTVHR (based on a comprehensive literature review as well as
clinical experience) in July 2014. Extensive discussions occurred during four face-to-face meetings and frequent
email communication until a consensus was reached. The CT-based CTVHR boundaries were defined by each
anatomical plane (cranial–caudal, lateral, or anterior–posterior) with or without tumor progression beyond the
uterine cervix at diagnosis. Since the availability of magnetic resonance imaging (MRI) with applicator insertion for
3D planning is currently limited, T2-weighted MRI obtained at diagnosis and just before brachytherapy without
applicator insertion was used as a reference for accurately estimating the tumor size and topography. Furthermore,
utilizing information from clinical examinations performed both at diagnosis and brachytherapy is strongly recom-
mended. In conclusion, these recommendations will serve as a brachytherapy protocol to be used at institutions
with limited availability of MRI for 3D treatment planning.
© The Author 2016. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
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INTRODUCTION
In radiation therapy for uterine cervical cancer, 3D image-guided
brachytherapy (3D-IGBT) using magnetic resonance imaging
(MRI) or computed tomography (CT) has shown promise for
improving local control without increasing the risk of severe compli-
cations. Since the publication of the target concept and terms for
MRI-based 3D-IGBT by the European Group of Curietherapie–
European Society for Therapeutic Radiology and Oncology (GEC-
ESTRO) in 2005, a 90% target dose (D90) delivered to the high-risk
clinical target volume (CTVHR) has proved to be a useful dose–
volume parameter that correlates with local control [1–3]. However,
the CTVHR was originally devised when MRI was used for treat-
ment planning (MRI-based CTVHR); hence, the parameters for
CT-based treatment planning (CT-based CTVHR) have not been
fully established.
Although MRI is the gold standard for 3D-IGBT for cervical can-
cer, its global application is still limited. Recent surveys on IGBT for
cervical cancer demonstrated that CT is the most commonly used
imaging modality for dose specification in clinical practice [4–7].
Brachytherapy for cervical cancer in Japan is rapidly transitioning
from 2D to 3D treatment planning. A Japanese questionnaire-based
survey conducted in 2012 revealed that 16% of institutes that perform
3D treatment planning primarily use CT; this percentage was
expected to increase to 53% over the following 3 years [8]. This sur-
vey also revealed that MRI availability for treatment planning is lim-
ited in brachytherapy, although utilization of MRI for diagnosis and
before commencing brachytherapy is possible at most centers [8].
Clinical outcomes at several Japanese institutions using 3D-IGBT
with CT have been reported [9–12]. When physicians contour CTV
using CT according to their respective institutional policies, the dose–
volume parameters to the target are likely more sensitive because
of poorer tumor visualization by CT compared with MRI [13].
Considering the fact that CT is a mainstay for 3D-IGBT in the major-
ity of institutions, the resulting dose uncertainty from such CT-based
CTV contouring must be minimized. Therefore, we conducted a
multi-institutional study of CT-based CTVHR delineation in order to
standardize 3D-IGBT application in regions where the availability of
MRI with applicator in place is limited.
MATERIALS AND METHODS
This study was initiated at the volition of the Working Group on
Gynecological Tumors committee, a branch of the Japanese
Radiation Oncology Study Group (JROSG). The working group
consisted of 15 members (from 14 institutes) with expertise in
gynecological radiation oncology. Eight institutions used CT as the
imaging modality for treatment planning of brachytherapy for cer-
vical cancer, three used both CT and MRI, two used CT and radi-
ography, and one used radiography alone.
During the first meeting, held in July 2014, the background and
aims of the multi-institutional collaborative study on CT-based CTVHR
were decided. Subsequently, researchers reviewed the international
guidelines (GEC ESTRO and the American Brachytherapy Society)
[1, 2, 13, 14] and then devised a timetable for developing recommen-
dations. In the second meeting, held in December 2014, a draft of bor-
der definitions for CT-based CTVHR was delivered using actual
patient CT images. Afterwards, the details of these definitions were
discussed for each anatomical plane (craniocaudal, lateral and anter-
ior–posterior) via e-mail. In the third meeting, in June 2015, cranial
and lateral margins were discussed at length, as negotiating these
details over email was cumbersome. In the fourth meeting, which was
held in July 2015, various issues were discussed, including the use of
CT and MR images as references, and definitions of CT-based
CTVHR. At the end of August 2015, a consensus was reached on fun-
damental recommendations, including the image acquisition protocols
required for CT-based CTVHR, integration of diagnostic MRI plus
information from clinical examinations, and CTVHR border definitions
on CT images. The first version was reviewed by two external advi-
sors; the value of MRI and limitations of CT in 3D-IGBT for cervical
cancer were updated based on discussions between the external advi-
sors and JROSG members. Finally, the revised recommendations were
completed and approved by all members in June 2016.
RESULTS
Definition of CTVHR
In our present recommendations, we defined CTVs according to
the imaging modality used when contouring for brachytherapy treat-
ment planning. These included (i) CT-based CTV: CT with appli-
cator insertion [13, 14], (ii) CT-based CTVHR: CT with applicator
insertion and MRI just before first brachytherapy [15], and (iii)
MRI-based CTVHR: MRI with applicator insertion [1, 2]. For all
CTV contouring modalities, clinical examination findings at the
time of brachytherapy were also used.
Fundamental policy for delineation
Our recommendations follow the guidelines of MRI-based CTVHR
according to the GEC-ESTRO recommendations [1, 2]. The funda-
mental policy for CT-based CTVHR delineation is to minimize both
inter/intraphysician variability of contouring, as well as to reduce
the discrepancy in contouring when compared with MRI-based
CTVHR. The CT-based CTVHR boundaries are classified by each
direction (cranial–caudal, lateral or anterior–posterior) with or with-
out tumor progression beyond the uterine cervix at diagnosis (see
the Results subsection below “CT-based CTVHR boundaries”).
Acquisition of CT images
CT with gynecological applicator insertion for planning is per-
formed in the same position as during actual treatment. The scope
is set to completely cover the uterus and vagina. Scanning should
commence from the level of the uterine fundus 3 cm or more in the
cranial direction, and caudally to the level of the vulva. The field of
view includes both sides of the pelvic wall, and the slice thickness
should be less than 3 mm. In principle, a supine position with the
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legs straightened is recommended, since CT images will be com-
pared with MR images obtained at diagnosis or just before brachy-
therapy. If CT with applicator in place is performed in the
lithotomy position, attention may have to be paid to anatomical
changes between the CT and MRI positions because the MR
images are acquired with straightened legs. CT will be performed at
every brachytherapy session. It should be noted that CT and MRI
findings are also influenced by image acquisition parameters (e.g.
slice thickness, uterine body angle/position that depends on the
presence/absence of gynecological applicator placement, contents of
the bowel/bladder, and organ movement during the acquisition).
Integration of findings of MR images and clinical
information with contouring
CT-based CTVHR contouring based on Fédération Internationale de
Gynécologie et d’Obstetrique (FIGO) clinical stage information alone
leads to large overestimation of width and volume compared with
MRI-based CTVHR [13, 16]. The use of information from clinical
examinations at the time of both diagnosis and brachytherapy is
strongly recommended for improving the accuracy of CT-based
CTVHR delineation [16]. T2-weighted MR images acquired at diag-
nosis and just before brachytherapy without applicator should rou-
tinely be used as a reference. MRI acquired just before brachytherapy
helps not only to evaluate the response to external beam radiation
therapy, but also to identify the extent of residual tumors (including
parametrial and cranial extensions) and plan suitable gynecological
applicator placement (e.g. adding interstitial needles).
Visual integration of the findings of MRI and information from
clinical examinations with those of CT images could reduce overesti-
mation of CT-based CTVHR and make it more consistent with MRI-
based CTVHR. On the other hand, target transfer from CTVHR
delineation on MRI without gynecological applicator insertion before
brachytherapy to CT with the applicator inserted at brachytherapy is
MRI-based GTV CT-based CTVHR
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Fig. 1. Caudal, cranial, lateral, anterior and posterior boundaries of a computed tomography (CT)-based high-risk clinical
target volume (CTVHR). FIGO Clinical Stage IB1: a case without tumor extension beyond the uterine cervix at diagnosis.
T2-weighted magnetic resonance imaging (MRI) in the sagittal plane (A) and transverse plane (B) at diagnosis, and in the
sagittal plane (C) and transverse plane (D) just before brachytherapy (BT). A plain CT image in the sagittal plane (E) and
transverse plane (F) at the time of first BT, and in the sagittal plane (G) and transverse plane (H) at the time of first BT with
CT-based CTVHR contouring. A plain CT image in the coronal plane (I) and transverse plane (J) at the time of first BT with
CT-based CTVHR contouring with a landmark at the upper border of the cervix. Gynecological applicators were placed for CT
but not for MRI. Pink line = MRI-based gross tumor volume (GTV), red line = CT-based CTVHR, short yellow arrow =
uterine isthmus, long yellow arrow = uterine artery.
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difficult because large anatomical changes may occur owing to appli-
cator insertion, vaginal packing, and the filling status of the bladder
and rectum. Moreover, collection of such image deformations was
incomplete because the deformable image registration software is still
undergoing improvements. Therefore, the tumor size and topog-
raphy on MRI just before brachytherapy will be used as the reference
in the present recommendations. When complex tumor volumes on
MRI without applicator insertion before brachytherapy are visually
translated into CT-based CTVHR contouring, there is a potential risk
of geographical misses for extensively large tumors with parametrial
or adjacent organ involvement [15]. Therefore, greater attentiveness
is necessary to minimize such risks in extensively large tumors when
determining their sizes and topographies using transverse, coronal
and sagittal plane images on MRI.
In principle, the CT-based CTVHR is contoured in the transverse
plane image. The uterine axis (perpendicular to the tandem axis) can
be used as an index. If available, comparing the position of the uterus
between sagittal MR images and sagittal reconstructed CT images is
recommended for improving the accuracy of CT-based CTVHR
delineation.
In contouring a second CT-based CTVHR, all previous clinical
information and MR images acquired just before the first brachy-
therapy session are integrated into the CT images acquired with
applicator insertion at the time of the second brachytherapy. In par-
ticular, cervical tumor response at each brachytherapy session, in
terms of size and topography, should be carefully evaluated by clin-
ical examination. The CT-based CTVHR at the first brachytherapy
should be referred to. The subsequent CT-based CTVHR is also
contoured by the same methods.
CT-based CTVHR boundaries
Caudal boundary
Cases without vaginal invasion at diagnosis. The caudal bound-
ary is defined as cervical tissue at the level of the tandem applicator
fringe. Any exophytic tumors (i.e. those that extend into the vaginal
cavity) at the time of brachytherapy should be included. CT-based
CTVHR contouring excludes applicators inserted (i.e. the fringe of
the tandem applicator, ovoid caps, ring applicator, and vaginal cylin-
der). Vaginal packing material and the vaginal vault are also
excluded (Fig. 1).
Cases with vaginal invasion at diagnosis. In addition to the caudal
boundary contoured in cases without vaginal invasion (see the sub-
section “Cases without vaginal invasion at diagnosis”), residual vagi-
nal tumor lesions at the time of brachytherapy are included. The
lowest boundary of the vaginal target is determined by referring to
either the distance between the caudal edge of the inserted applicator
and the caudal edge of the vaginal tumor (for the upper half of the
vaginal tumor), or the distance between the external urethral open-
ing and the caudal edge of the vaginal tumor (for the lower half of










MRI-based GTV CT-based CTVHR
MRI at diagnosis MRI just
before BT
Fig. 2. Caudal boundary of a computed tomography (CT)-based high-risk clinical target volume (CTVHR). FIGO Clinical
Stage IIIA: a case with vaginal invasion at diagnosis presented good response at the time of first brachytherapy (BT).
T2-weighted magnetic resonance imaging (MRI) in the sagittal plane (A) and transverse plane (B) at diagnosis, and in the
sagittal plane (C) and transverse plane (D) before BT. A plain CT image in the sagittal plane (E) and transverse plane
(F) at the time of first BT, and in the sagittal plane (G) and transverse plane (H) at the time of first BT with CT-based
CTVHR contouring. Gynecological applicators were placed for CT but not for MRI. Pink line = MRI-based gross tumor
volume (GTV), red line = CT-based CTVHR, yellow arrowhead = calcification.
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MRI-based GTV CT-based CTVHR
Fig. 3. Cranial boundary of a computed tomography (CT)-based high-risk clinical target volume (CTVHR). FIGO Clinical
Stage IIB: a case with uterine corpus invasion at diagnosis showed good response at the time of first brachytherapy (BT).
T2-weighted magnetic resonance imaging (MRI) in the sagittal plane (A) and transverse plane (B) at diagnosis, and in the
sagittal plane (C) and transverse plane (D) before BT. A plain CT image in the sagittal plane (E) and transverse plane (F) at
the time of first BT, and in the sagittal plane (G) and transverse plane (H) at the time of first BT with CT-based CTVHR
contouring. Gynecological applicators were placed for CT but not for MRI. Pink line = MRI-based gross tumor volume
(GTV), red line = CT-based CTVHR, yellow arrowhead = calcification. Calcification recognized in the periphery of the uterus
will be helpful for delineating the border.






CT at BT 1st CT at BT 1st
(with CTVHR)
MRI-based GTV CT-based CTVHR
A B C D
Fig. 4. Lateral boundary of a computed tomography (CT)-based high-risk clinical target volume (CTVHR). FIGO Clinical
Stage IIIB: a case with tumor progression to the left pelvic wall at diagnosis presented poor response at the time of first
brachytherapy (BT). T2-weighted magnetic resonance imaging (MRI) transverse image at diagnosis (A) and before BT (B).
A plain CT transverse image at the time of first BT (C) and at the time of first BT with CT-based CTVHR contouring (D).
Gynecological applicators including two interstitial needles were placed for CT but not for MRI. Pink line = MRI-based gross
tumor volume (GTV), red line = CT-based CTVHR, yellow arrow = interstitial needle, d1 = width of MRI-based CTVHR,
d2 = anteroposterior diameter of MRI-based CTVHR. Tracing the diameter of MRI-based CTVHR (d1 and d2) on the CT
image is helpful for minimizing overestimation of the border between CT-based CTVHR and adjacent organs.
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the vaginal tumor); both can be confirmed during applicator inser-
tion. The thickness of the vaginal target is defined as the entire vagi-
nal wall, including tumors identified on CT. The thickness and
clockwise direction of tumor progression are determined by referring
to MR images acquired just before brachytherapy as well as clinical
examination findings (Fig. 2).
Cranial boundary
Cases without uterine corpus invasion at diagnosis. The cranial
boundary is defined as the upper margin of the uterine cervix at the
time of brachytherapy. Contouring starts with the junction of the
uterine artery by referring to the upper and lower slices in the trans-
verse plane image or the isthmus of the uterus that correspond to
the upper border of the cervix on the serosal side. In most patients,
the isthmus of the uterus could be determined based on the sagittal
or coronal plane images at the time of brachytherapy. MR images
taken just before brachytherapy are useful references. Once the
upper border of the serosal side is determined, it will be enclosed at
a level 1 cm in the cranial direction in a cone-shaped contour that cov-
ers the conical cervical apex along with the uterine cavity (Fig. 1).
Cases with uterine corpus invasion at diagnosis. If the borders of
the residual tumor extend beyond the cervix, the cranial boundary is
defined as the upper border of the residual tumor at the time of
brachytherapy of the uterine corpus; i.e. the upper border of the
abnormal signal intensity (including the gray zone), believed to be
residual tumor, as detected on MRI just before brachytherapy
(Fig. 3). Contouring starts with the cervical tumor towards the uter-
ine fundus, referring to transverse- and sagittal-plane MR images
acquired at diagnosis and just before brachytherapy.
If a residual tumor exists in the cervix or if the tumor has disap-
peared, the cranial boundary is defined similarly to cases with no
corpus invasion at diagnosis, as described above (see the subsection
“Cases without uterine corpus invasion at diagnosis”).
Lateral boundary
Cases without parametrial invasion at diagnosis. The lateral
boundary is defined as the border between the uterine tissue (soft
tissue density on CT) and the surrounding adipose tissue (low dens-
ity on CT) at the time of brachytherapy. The intestinal tract, adnexa,
ascites, and visible linear structures that run laterally (e.g. vessels,
nerves and fibrous structures, but not tumor extensions) are
excluded. Calcification recognized in the periphery of the uterus on
CT images will be helpful for delineating the border in some cases,
although it is usually difficult to identify such features on MR images.
It is essential to carefully refer to MRI findings at brachytherapy and
just before, as well as to clinical examination findings (Fig. 1).
Cases with parametrial invasion at diagnosis. The lateral bound-
ary is defined as the border between the uterine tissue or residual
tumor (soft tissue density on CT) and surrounding adipose tissue
(low density on CT) at the time of brachytherapy. The lateral bor-
der of the CT-based CTVHR should be determined carefully by
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Fig. 5. Posterior boundary of a computed tomography (CT)-based high-risk clinical target volume (CTVHR). FIGO Clinical
Stage IVA: a case with invasion of the rectum at diagnosis. T2-weighted magnetic resonance imaging (MRI) in the sagittal
plane (A) and transverse plane (B) at diagnosis, and in the sagittal plane (C) and transverse plane (D) before BT. A plain CT
image in the sagittal plane (E) and transverse plane (F) at the time of first BT, and in the sagittal plane (G) and transverse
plane (H) at the time of first BT with CT-based CTVHR contouring. Gynecological applicators, including three interstitial
needles, were placed for CT but not for MRI. Pink line = MRI-based gross tumor volume (GTV), red line = CT-based
CTVHR, yellow arrow = interstitial needle.
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Posterior boundary
Cases without tumor invasion to the rectum or sigmoid colon wall
at diagnosis. The posterior boundary is defined as the border between
the uterine tissue at the time of brachytherapy or the residual tumor
(soft tissue density on CT), whichever is more posterior, and the adi-
pose tissue (low density on CT). If no adipose tissue is observed, the
posterior border of the uterine tissue is determined without including
the walls of the rectum, sigmoid colon, and small bowels by referring
to the upper and lower slices of the transverse plane image or those of
the sagittal plane of the reconstructed images (Fig. 1).
Cases with invasion of the rectum or sigmoid colon wall at
diagnosis. Invasion of the rectum or sigmoid colon that is evident
at the time of brachytherapy is included (Fig. 5). Tumor progres-
sion is determined by referring to MR images (at diagnosis and just
before brachytherapy). Other sites in the posterior boundary are
handled as described for cases without tumor invasion of the rectum
or sigmoid colon wall at diagnosis (see the subsection “Cases with-
out tumor invasion to the rectum or sigmoid colon wall at
diagnosis”). Of note, rectum or sigmoid colon wall invasion is con-
firmed when tumor invasion of the muscle layer is diagnosed inde-
pendently of mucosal invasion (which is the correct diagnosis
criterion of rectal invasion for FIGO Stage IVA tumors).
Anterior boundary
Cases without tumor invasion of the bladder wall at
diagnosis. The anterior boundary is defined as the border between the
uterine tissue or the residual tumor (soft tissue density on CT) at the
time of brachytherapy, whichever is more anterior, and the adipose tis-
sue (low density on CT). If no adipose tissue is observed, the anterior
border of the uterine tissue is determined without including the bladder
wall by referring to the upper and lower slices of the transverse plane
image or those of the sagittal plane of the reconstructed image (Fig. 1).
Cases with invasion of the bladder wall at diagnosis. The residual
bladder invasion that clearly remains at the time of brachytherapy is
included (Fig. 6). Tumor progression is determined by referring to
MR images acquired at diagnosis and just before brachytherapy. Other
sites in the anterior boundary are managed as described in cases with-
out tumor invasion of the bladder wall at diagnosis (see the subsection
“Cases without tumor invasion of the bladder wall at diagnosis”). Of
note, bladder wall invasion is confirmed when tumor invasion of the
muscle layer is diagnosed independently of mucosal invasion (which is
the correct diagnosis criterion of bladder invasion for FIGO Stage IVA
tumors). When the intestinal tract is close to the anterior uterine tis-
sue, the posterior margin policy for the rectum or sigmoid colon (see
the subsection “Cases without tumor invasion to the rectum or sig-
moid colon wall at diagnosis”) is applied.
The CT-based CTVHR boundaries described above are shown in
Table 1.
DISCUSSION
Several principles of CT-based CTV have been reported; they are
based mainly on the consensus of gynecologic radiation oncology
Bladder invasion
Bladder invasion
BladderMRI-based GTV CT-based CTVHR










Fig. 6. Anterior boundary of a computed tomography (CT)-based high-risk clinical target volume (CTVHR). FIGO Clinical
Stage IVA: a case with invasion of the bladder at diagnosis. T2-weighted magnetic resonance imaging (MRI) in the sagittal
plane (A) and transverse plane (B) at diagnosis, and in the sagittal plane (C) and transverse plane (D) just before
brachytherapy (BT). A plain CT image in the sagittal plane (E) and transverse plane (F) at the time of BT, and in the sagittal
plane (G) and transverse plane (H) at the time of BT with CT-based CTVHR contouring. Gynecological applicators were
placed for CT but not for MRI. Pink line = MRI-based gross tumor volume (GTV), red line = CT-based CTVHR.
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experts [13, 14]. In these reports, however, MR images acquired
before or at brachytherapy were not routinely used for contouring
the CT-based CTV. We believe that MRI should be used whenever
possible, as it is apparently superior to CT in this regard. In our cur-
rent recommendations, the intent was to develop a CT-based
CTVHR that is as consistent with the MRI-based CTVHR devised by
the gynecological (GYN) GEC ESTRO as possible. To our knowl-
edge, our CT-based CTVHR is the first to incorporate MRI (at diag-
nosis and just before brachytherapy) and clinical examination
findings (at diagnosis and brachytherapy) with CT images with
applicator in place at brachytherapy.
Cranial boundary
According to the GYN GEC ESTRO recommendation, the cranial
boundary of CTVHR is defined as the cranial border of the cervix or
a macroscopic residual tumor at brachytherapy [1]. When the cer-
vical tumor does not extend beyond the cervix, the junction of the
uterine artery as identified on plane CT images, and/or the isthmus
of the uterus as exposed by CT, are useful for determining the
upper border of the serosal side.
On the other hand, in cases with uterine body extensions, an
inter-observer comparison study on MRI-based CTVHR reported
that image quality and window level can result in over- or
Table 1. Contouring recommendations for a computed tomography–based high-risk clinical target volume
Direction and tumor extension Contouring recommendations
1. Caudal boundary
(a) Vaginal invasion (−) Contouring commences at the cervical tissue at the level of the tandem applicator fringe. The
applicators are excluded, as are the vaginal packing material and vaginal vault.
(b) Vaginal invasion (+) In addition to ‘1a’, the residual vaginal tumor lesions at the time of brachytherapy are included.
2. Cranial boundary
(a) Uterine corpus invasion (−) Defined as the upper margin of the uterine cervix. Contouring starts at the junction of the uterine
artery or isthmus. The upper border of the serosal side is enclosed at a level of 1 cm in the cranial
direction in a cone-shaped contour, along with the uterine cavity.
(b) Uterine corpus invasion (+) Defined as the upper border of the residual tumor (i.e. the abnormal signal intensity) as detected on
MRI just before brachytherapy of the uterine corpus.
3. Lateral boundary
(a) Parametrial invasion (−) Consists of the border between the uterine tissue and surrounding adipose tissue at the time of
brachytherapy. The intestinal tract, adnexa, ascites, and visible linear structures that run laterally (e.g.
vessels, nerves and fibrous structures) are excluded.
(b) Parametrial invasion (+) Consists of the border between the uterine tissue or residual tumor and the surrounding adipose tissue
at the time of brachytherapy.
4. Posterior boundary
(a) Rectum or sigmoid colon wall
invasion (−)
Defined as the border between the uterine tissue or residual tumor, whichever is more posterior, and
adipose tissue.
(b) Rectum or sigmoid colon wall
invasion (+)
Invasion of the rectum or sigmoid colon that is evident at the time of brachytherapy is included.
Tumor progression is determined by reviewing MR images. Other posterior boundary sites are
managed as described in ‘4a’.
5. Anterior boundary
(a) Bladder wall invasion (−) Includes the border between the uterine tissue or residual tumor, whichever is more anterior, and the
adipose tissue.
(b) Bladder wall invasion (+) Any residual bladder-invading tumor tissue that is clearly evident at the time of brachytherapy is
included. Tumor progression is determined by reviewing MR images. Other anterior boundary sites
are managed as described in ‘5a’.
6. General Clinical examination findings at the time of brachytherapy should be taken into account.
CT = computed tomography, MR(I) = magnetic resonance (imaging).








niversity Library user on 28 August 2020
underestimation of tumor boundaries, which was the most frequent
cause of inter-observer variability during delineation [17]. This study
stressed the importance of imaging quality as well as physicians’ skill
in diagnostic imaging, because MRI (but not CT or clinical examin-
ation) can help identify the residual tumor in the uterine body at
brachytherapy. In particular, the cranial boundary in CT-based
CTVHR appears to be equivalent to MRI-based CTVHR when com-
paring the reconstructed sagittal CT images with applicator insertion
to sagittal MR images acquired just before brachytherapy.
Caudal boundary
The vagina is one of the organs at risk during 3D-IGBT for cervical
cancer; it is important to consider the proximal vaginal dose to
avoid late vaginal complications [18]. The soft tissue density of the
prolapsed vaginal vault may cause overestimation of CT-based
CTVHR contouring despite no tumor being present, especially in
young patients. Obtaining a baseline distance using MRI before
brachytherapy for comparison with CT with applicators in place will
be helpful.
For cases with vaginal invasion at diagnosis, adding information
from clinical examinations at brachytherapy to imaging data is useful
for precisely identifying the vaginal tumor extension. However, it
has not been fully decided how physicians should incorporate such
clinical information into contouring of the caudal boundary in CT-
based CTVHR. The present recommendations proposed the use of
the distance between the caudal edge of the inserted applicator and
the caudal edge of the vaginal tumor, or the distance between the
external urethral opening and the caudal edge of the vaginal tumor,
based on clinical examination. Additionally, we recommend the use
of thickness and clockwise direction data of tumor progression that
can be determined by referring to MR images and clinical examina-
tions at brachytherapy.
Lateral boundary
In a comparison study of MRI-based CTVHR with CT-based CTV
for locally advanced cervical cancer, the conformity index of con-
touring was slightly higher for CT than for MRI in all three tested
scenarios, suggesting better distinction on CT between the involved
‘gray’ region and the non-involvement of the parametria [14].
However, a comparison of MRI and CT for CTV delineation in
3D-IGBT for cervical cancer has revealed that CT-based contouring
overestimates the contour width [13]. Therefore, one of the issues
discussed during the meetings of experts was how to minimize the
difference in width between CT-based CTVHR and MRI-based
CTVHR. The first recommendation was to reduce the slice thickness
to <3 mm to improve imaging quality. In comparison studies on
CTV contouring between CT and MRI, CT slice thickness was
reduced from 5 mm in the first study to 1.25 mm in the second
study, which likely contributed to improved accuracy in contouring
when using CT [13, 14]. Second, we recommended that the lateral
border of the CT-based CTVHR should be determined carefully,
and MRI findings just before brachytherapy should be referred to.
If MRI data with a tandem applicator are available, that would be
valuable for measuring the distance between the center of the tan-
dem applicator and the anterior–posterior/left–right borders of the
MRI-based CTVHR. For example, in cases without adipose tissue
density between the cervical tumor and adjacent bowels on CT,
referring to the distance based on MR imaging just before brachy-
therapy will be useful for determining the border. Third, we recom-
mended careful exclusion of the visible linear structures that run
laterally (e.g. the vessels, nerves and non-tumor fibrous structures);
this was previously defined in a consensus-based guideline for CTV
of the primary tumor on external beam radiotherapy for intact cervical
cancer [19].
Limitations
The GEC-ESTRO defined intermediate risk clinical target volume
(MRI-based CTVIR) in their first published recommendations [1].
Certain dosages are usually administered to MRI-based CTVIR that
are lower than those used for MRI-based CTVHR. However, clinical
data on the dose–response relationship in MRI-based CTVIR are
still limited [20]. While the ‘CT-based CTVIR’ definition and dose
prescriptions for 3D treatment planning of brachytherapy are
important, this subject is beyond the scope of the current study.
Defining CT-based CTVIR and dose prescriptions for 3D treatment
planning will be undertaken in a future study.
CONCLUSION
We have developed a set of recommendations aimed at defining the
CT-based CTVHR for 3D-IGBT in cervical cancer patients. The
recommendations will be introduced into routine practice for 3D-
IGBT and will also be used in clinical trials aimed at developing
future brachytherapy protocols for institutions where MRI availabil-
ity for 3D treatment planning is limited.
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